+++NEWS AUS DER ENERGIEPOLITIK+++
Zalicus Inc. , a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported successful results from a phase 1 clinical study to evaluate multiple modified-release formulations of Z944, a novel, oral, T-type calcium channel modulator in development for the treatment of pain....Zalicus Updates Progress on Z944 Clinical Development
Keine Kommentare:
Kommentar veröffentlichen